{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:33:50Z","timestamp":1790274830225,"version":"4.1.0"},"publisher-location":"Cham","reference-count":153,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319221076","type":"print"},{"value":"9783319221083","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/5584_2016_123","type":"book-chapter","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T14:20:08Z","timestamp":1472826008000},"page":"307-324","source":"Crossref","is-referenced-by-count":27,"title":["Role of P2Y12 Receptor in Thrombosis"],"prefix":"10.1007","author":[{"given":"Yaqi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongren","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"issue":"3","key":"123_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1113\/jphysiol.1929.sp002608","volume":"68","author":"AN Drury","year":"1929","unstructured":"Drury AN, Szent-Gyorgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68(3):213\u2013237","journal-title":"J Physiol"},{"issue":"3","key":"123_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(94)00048-4","volume":"64","author":"MP Abbracchio","year":"1994","unstructured":"Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64(3):445\u2013475","journal-title":"Pharmacol Ther"},{"key":"123_CR3","first-page":"107","volume-title":"Cell membrane receptors for drugs and hormones: a multidisciplinary approach","author":"G Burnstock","year":"1978","unstructured":"Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub RW, Bolis L (eds) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven, New York, pp 107\u2013118"},{"issue":"1","key":"123_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0014-5793(97)00022-7","volume":"403","author":"C Leon","year":"1997","unstructured":"Leon C et al (1997) The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 403(1):26\u201330","journal-title":"FEBS Lett"},{"issue":"4","key":"123_CR5","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1074\/jbc.273.4.2030","volume":"273","author":"J Jin","year":"1998","unstructured":"Jin J, Daniel JL, Kunapuli SP (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273(4):2030\u20132034","journal-title":"J Biol Chem"},{"issue":"6817","key":"123_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopeter","year":"2001","unstructured":"Hollopeter G et al (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817):202\u2013207","journal-title":"Nature"},{"issue":"4","key":"123_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF02982079","volume":"74","author":"C Gachet","year":"2001","unstructured":"Gachet C (2001) Identification, characterization, and inhibition of the platelet ADP receptors. Int J Hematol 74(4):375\u2013381","journal-title":"Int J Hematol"},{"issue":"2","key":"123_CR8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2332\/allergolint.12-OA-0496","volume":"62","author":"H Shirasaki","year":"2013","unstructured":"Shirasaki H et al (2013) Expression and localization of purinergic P2Y(12) receptor in human nasal mucosa. Allergol Int 62(2):239\u2013244","journal-title":"Allergol Int"},{"issue":"3","key":"123_CR9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00395-009-0073-8","volume":"105","author":"P Diehl","year":"2010","unstructured":"Diehl P et al (2010) Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 105(3):379\u2013387","journal-title":"Basic Res Cardiol"},{"key":"123_CR10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2172-5-16","volume":"5","author":"L Wang","year":"2004","unstructured":"Wang L et al (2004) P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 5:16","journal-title":"BMC Immunol"},{"issue":"10","key":"123_CR11","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","volume":"101","author":"Z Ding","year":"2003","unstructured":"Ding Z et al (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101(10):3908\u20133914","journal-title":"Blood"},{"issue":"11","key":"123_CR12","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/j.1538-7836.2006.02192.x","volume":"4","author":"BN Kahner","year":"2006","unstructured":"Kahner BN et al (2006) Nucleotide receptor signaling in platelets. J Thromb Haemost 4(11):2317\u20132326","journal-title":"J Thromb Haemost"},{"issue":"26","key":"123_CR13","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.1074\/jbc.M202212200","volume":"277","author":"D Woulfe","year":"2002","unstructured":"Woulfe D et al (2002) Activation of Rap1B by G(i) family members in platelets. J Biol Chem 277(26):23382\u201323390","journal-title":"J Biol Chem"},{"issue":"3","key":"123_CR14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.pharmthera.2005.08.014","volume":"110","author":"I Kugelgen von","year":"2006","unstructured":"von Kugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110(3):415\u2013432","journal-title":"Pharmacol Ther"},{"issue":"1","key":"123_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/09537104.2011.594190","volume":"23","author":"F Lombardi","year":"2012","unstructured":"Lombardi F et al (2012) Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding. Platelets 23(1):17\u201325","journal-title":"Platelets"},{"issue":"12","key":"123_CR16","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1046\/j.1432-1327.2001.02252.x","volume":"268","author":"SM Jung","year":"2001","unstructured":"Jung SM, Moroi M (2001) Platelet collagen receptor integrin alpha2beta1 activation involves differential participation of ADP-receptor subtypes P2Y1 and P2Y12 but not intracellular calcium change. Eur J Biochem 268(12):3513\u20133522","journal-title":"Eur J Biochem"},{"issue":"3","key":"123_CR17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","volume":"112","author":"P Andre","year":"2003","unstructured":"Andre P et al (2003) P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112(3):398\u2013406","journal-title":"J Clin Invest"},{"issue":"1","key":"123_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/0953710021000062914","volume":"14","author":"IA Jagroop","year":"2003","unstructured":"Jagroop IA, Burnstock G, Mikhailidis DP (2003) Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 14(1):15\u201320","journal-title":"Platelets"},{"issue":"8","key":"123_CR19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/09537104.2011.645924","volume":"23","author":"E Tournoij","year":"2012","unstructured":"Tournoij E et al (2012) The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor. Platelets 23(8):617\u2013625","journal-title":"Platelets"},{"issue":"12","key":"123_CR20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","volume":"107","author":"CJ Foster","year":"2001","unstructured":"Foster CJ et al (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107(12):1591\u20131598","journal-title":"J Clin Invest"},{"issue":"10","key":"123_CR21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/13522","volume":"5","author":"JE Fabre","year":"1999","unstructured":"Fabre JE et al (1999) Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 5(10):1199\u20131202","journal-title":"Nat Med"},{"issue":"12","key":"123_CR22","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8399","volume":"104","author":"C Leon","year":"1999","unstructured":"Leon C et al (1999) Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 104(12):1731\u20131737","journal-title":"J Clin Invest"},{"issue":"7498","key":"123_CR23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","volume":"509","author":"K Zhang","year":"2014","unstructured":"Zhang K et al (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 509(7498):115\u2013118","journal-title":"Nature"},{"issue":"5","key":"123_CR24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/mol.62.5.1249","volume":"62","author":"GL Waldo","year":"2002","unstructured":"Waldo GL et al (2002) Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 62(5):1249\u20131257","journal-title":"Mol Pharmacol"},{"issue":"3","key":"123_CR25","doi-asserted-by":"crossref","first-page":"C559","DOI":"10.1152\/ajpcell.00401.2004","volume":"288","author":"Z Ding","year":"2005","unstructured":"Ding Z et al (2005) Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling. Am J Physiol Cell Physiol 288(3):C559\u201367","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"123_CR26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.phrs.2010.05.007","volume":"62","author":"P Ohlmann","year":"2010","unstructured":"Ohlmann P et al (2010) Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2\u2032-deoxyadenosine-3\u2032,5\u2032-bisphosphate ([(125)I]MRS2500). Pharmacol Res 62(4):344\u2013351","journal-title":"Pharmacol Res"},{"issue":"5","key":"123_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood-2011-02-334524","volume":"118","author":"EM Battinelli","year":"2011","unstructured":"Battinelli EM, Markens BA, Italiano JE Jr (2011) Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118(5):1359\u20131369","journal-title":"Blood"},{"issue":"5","key":"123_CR28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/tra.12054","volume":"14","author":"MR Cunningham","year":"2013","unstructured":"Cunningham MR et al (2013) Differential endosomal sorting of a novel P2Y12 purinoreceptor mutant. Traffic 14(5):585\u2013598","journal-title":"Traffic"},{"issue":"10","key":"123_CR29","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1161\/01.ATV.0000092127.16125.E6","volume":"23","author":"C Leon","year":"2003","unstructured":"Leon C et al (2003) Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23(10):1941\u20131947","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"123_CR30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.pharmthera.2005.03.009","volume":"108","author":"C Gachet","year":"2005","unstructured":"Gachet C (2005) The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 108(2):180\u2013192","journal-title":"Pharmacol Ther"},{"issue":"21","key":"123_CR31","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1074\/jbc.274.21.14639","volume":"274","author":"C Hoffmann","year":"1999","unstructured":"Hoffmann C et al (1999) The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem 274(21):14639\u201314647","journal-title":"J Biol Chem"},{"issue":"11","key":"123_CR32","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2008.03136.x","volume":"6","author":"I Algaier","year":"2008","unstructured":"Algaier I et al (2008) Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 6(11):1908\u201314","journal-title":"J Thromb Haemost"},{"issue":"29","key":"123_CR33","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.0510446103","volume":"103","author":"P Savi","year":"2006","unstructured":"Savi P et al (2006) The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 103(29):11069\u201311074","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"123_CR34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1538-7836.2008.03202.x","volume":"7","author":"Z Ding","year":"2009","unstructured":"Ding Z et al (2009) Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y receptor when interacting with antagonists. J Thromb Haemost 7(1):232\u2013234","journal-title":"J Thromb Haemost"},{"issue":"1","key":"123_CR35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/mol.105.014654","volume":"69","author":"Z Ding","year":"2006","unstructured":"Ding Z, Kim S, Kunapuli SP (2006) Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor. Mol Pharmacol 69(1):338\u2013345","journal-title":"Mol Pharmacol"},{"issue":"4","key":"123_CR36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1538-7836.2008.02896.x","volume":"6","author":"JR Dilks","year":"2008","unstructured":"Dilks JR, Flaumenhaft R (2008) Fluoxetine (Prozac) augments platelet activation mediated through protease-activated receptors. J Thromb Haemost 6(4):705\u2013708","journal-title":"J Thromb Haemost"},{"issue":"10","key":"123_CR37","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1538-7836.2012.04894.x","volume":"10","author":"Y Zhang","year":"2012","unstructured":"Zhang Y et al (2012) Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12. J Thromb Haemost 10(10):2149\u20132157","journal-title":"J Thromb Haemost"},{"issue":"14","key":"123_CR38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. New Engl J Med 368(14):1303\u20131313","journal-title":"New Engl J Med"},{"issue":"1","key":"123_CR39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.12063","volume":"11","author":"S Zhang","year":"2013","unstructured":"Zhang S et al (2013) P2Y12 protects platelets from apoptosis via PI3k-dependent Bak\/Bax inactivation. J Thromb Haemost 11(1):149\u2013160","journal-title":"J Thromb Haemost"},{"issue":"19","key":"123_CR40","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"CP Cannon","year":"2007","unstructured":"Cannon CP et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50(19):1844\u20131851","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"123_CR41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted S et al (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27(9):1038\u20131047","journal-title":"Eur Heart J"},{"key":"123_CR42","doi-asserted-by":"crossref","unstructured":"Van Giezen JJ et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7(9):1556\u20131565","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"issue":"9990","key":"123_CR43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","volume":"386","author":"JL Mega","year":"2015","unstructured":"Mega JL, Simon T (2015) Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 386(9990):281\u201391","journal-title":"Lancet"},{"issue":"11","key":"123_CR44","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1538-7836.2004.00926.x","volume":"2","author":"G Kauffenstein","year":"2004","unstructured":"Kauffenstein G et al (2004) Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2(11):1980\u20131988","journal-title":"J Thromb Haemost"},{"issue":"48","key":"123_CR45","doi-asserted-by":"crossref","first-page":"46035","DOI":"10.1074\/jbc.M208519200","volume":"277","author":"J Yang","year":"2002","unstructured":"Yang J et al (2002) Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 277(48):46035\u201346042","journal-title":"J Biol Chem"},{"issue":"9","key":"123_CR46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0006-2952(01)00760-2","volume":"62","author":"UR Schwarz","year":"2001","unstructured":"Schwarz UR, Walter U, Eigenthaler M (2001) Taming platelets with cyclic nucleotides. Biochem Pharmacol 62(9):1153\u20131161","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"123_CR47","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V94.12.4156","volume":"94","author":"C Trumel","year":"1999","unstructured":"Trumel C et al (1999) A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 94(12):4156\u20134165","journal-title":"Blood"},{"issue":"2","key":"123_CR48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0014-5793(01)02824-1","volume":"505","author":"G Kauffenstein","year":"2001","unstructured":"Kauffenstein G et al (2001) The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin \u2013 a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett 505(2):281\u2013290","journal-title":"FEBS Lett"},{"issue":"1","key":"123_CR49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1074\/jbc.M204821200","volume":"278","author":"P Lova","year":"2003","unstructured":"Lova P et al (2003) A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J Biol Chem 278(1):131\u2013138","journal-title":"J Biol Chem"},{"issue":"6","key":"123_CR50","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1074\/jbc.M306162200","volume":"279","author":"S Kim","year":"2004","unstructured":"Kim S, Jin J, Kunapuli SP (2004) Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 279(6):4186\u20134195","journal-title":"J Biol Chem"},{"issue":"9","key":"123_CR51","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2006-03-010330","volume":"108","author":"H Shankar","year":"2006","unstructured":"Shankar H et al (2006) G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 108(9):3027\u20133034","journal-title":"Blood"},{"issue":"42","key":"123_CR52","doi-asserted-by":"crossref","first-page":"39493","DOI":"10.1074\/jbc.M207256200","volume":"277","author":"B Nieswandt","year":"2002","unstructured":"Nieswandt B et al (2002) Costimulation of Gi- and G12\/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem 277(42):39493\u201339498","journal-title":"J Biol Chem"},{"issue":"5","key":"123_CR53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.V55.5.841.841","volume":"55","author":"EI Peerschke","year":"1980","unstructured":"Peerschke EI et al (1980) Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 55(5):841\u2013847","journal-title":"Blood"},{"issue":"8","key":"123_CR54","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2005.01.034","volume":"45","author":"TA Nguyen","year":"2005","unstructured":"Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45(8):1157\u20131164","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"123_CR55","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2006-03-006338","volume":"108","author":"JM Cosemans","year":"2006","unstructured":"Cosemans JM et al (2006) Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108(9):3045\u20133052","journal-title":"Blood"},{"issue":"6","key":"123_CR56","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1538-7836.2006.01941.x","volume":"4","author":"T Kamae","year":"2006","unstructured":"Kamae T et al (2006) Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation. J Thromb Haemost 4(6):1379\u20131387","journal-title":"J Thromb Haemost"},{"issue":"1\u20133","key":"123_CR57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0014-5793(03)01430-3","volume":"556","author":"S Roger","year":"2004","unstructured":"Roger S et al (2004) Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett 556(1\u20133):227\u2013235","journal-title":"FEBS Lett"},{"issue":"1","key":"123_CR58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1160\/TH03-12-0729","volume":"92","author":"K Falker","year":"2004","unstructured":"Falker K, Lange D, Presek P (2004) ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets. Thromb Haemost 92(1):114\u2013123","journal-title":"Thromb Haemost"},{"issue":"2","key":"123_CR59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/BJ20061584","volume":"404","author":"A Garcia","year":"2007","unstructured":"Garcia A et al (2007) Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochem J 404(2):299\u2013308","journal-title":"Biochem J"},{"issue":"2","key":"123_CR60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/BJ20100166","volume":"429","author":"A Garcia","year":"2010","unstructured":"Garcia A et al (2010) Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 429(2):369\u2013377","journal-title":"Biochem J"},{"issue":"1","key":"123_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.114.091595","volume":"86","author":"A Khan","year":"2014","unstructured":"Khan A et al (2014) The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol 86(1):1\u201311","journal-title":"Mol Pharmacol"},{"issue":"5","key":"123_CR62","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jth.12552","volume":"12","author":"SF Moore","year":"2014","unstructured":"Moore SF, Hunter RW, Hers I (2014) Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets. J Thromb Haemost 12(5):748\u2013760","journal-title":"J Thromb Haemost"},{"issue":"3","key":"123_CR63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1476-5381.2010.00921.x","volume":"161","author":"CC Wu","year":"2010","unstructured":"Wu CC et al (2010) The roles and mechanisms of PAR4 and P2Y12\/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol 161(3):643\u2013658","journal-title":"Br J Pharmacol"},{"issue":"7","key":"123_CR64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/09537100500163424","volume":"16","author":"AR Hardy","year":"2005","unstructured":"Hardy AR, Hill DJ, Poole AW (2005) Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism. Platelets 16(7):415\u2013429","journal-title":"Platelets"},{"issue":"6","key":"123_CR65","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1538-7836.2004.00741.x","volume":"2","author":"TM Quinton","year":"2004","unstructured":"Quinton TM et al (2004) Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. J Thromb Haemost 2(6):978\u2013984","journal-title":"J Thromb Haemost"},{"issue":"3","key":"123_CR66","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.ATV.0000057809.32354.22","volume":"23","author":"MA Gestel van","year":"2003","unstructured":"van Gestel MA et al (2003) In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 23(3):518\u2013523","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"123_CR67","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1538-7836.2008.03111.x","volume":"6","author":"JJ Lopez","year":"2008","unstructured":"Lopez JJ et al (2008) Thrombin induces activation and translocation of Bid, Bax and Bak to the mitochondria in human platelets. J Thromb Haemost 6(10):1780\u20131788","journal-title":"J Thromb Haemost"},{"issue":"18","key":"123_CR68","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","volume":"123","author":"CN Morrell","year":"2014","unstructured":"Morrell CN et al (2014) Emerging roles for platelets as immune and inflammatory cells. Blood 123(18):2759\u20132767","journal-title":"Blood"},{"issue":"4","key":"123_CR69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/ATVBAHA.110.220467","volume":"31","author":"Y Liu","year":"2011","unstructured":"Liu Y et al (2011) Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol 31(4):834\u2013841","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"123_CR70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.RES.0000252802.25497.b7","volume":"100","author":"P Hundelshausen von","year":"2007","unstructured":"von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100(1):27\u201340","journal-title":"Circ Res"},{"issue":"2","key":"123_CR71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","volume":"21","author":"A Zarbock","year":"2007","unstructured":"Zarbock A, Polanowska-Grabowska RK, Ley K (2007) Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 21(2):99\u2013111","journal-title":"Blood Rev"},{"issue":"11","key":"123_CR72","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1084\/jem.20091240","volume":"206","author":"S Paruchuri","year":"2009","unstructured":"Paruchuri S et al (2009) Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206(11):2543\u20132555","journal-title":"J Exp Med"},{"issue":"5965","key":"123_CR73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.1181928","volume":"327","author":"E Boilard","year":"2010","unstructured":"Boilard E et al (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327(5965):580\u2013583","journal-title":"Science"},{"issue":"10","key":"123_CR74","doi-asserted-by":"crossref","first-page":"e26035","DOI":"10.1371\/journal.pone.0026035","volume":"6","author":"AE Garcia","year":"2011","unstructured":"Garcia AE et al (2011) Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One 6(10):e26035","journal-title":"PLoS One"},{"issue":"2","key":"123_CR75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1189\/jlb.1012518","volume":"95","author":"E Liverani","year":"2014","unstructured":"Liverani E et al (2014) LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukoc Biol 95(2):313\u2013323","journal-title":"J Leukoc Biol"},{"issue":"3","key":"123_CR76","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/SHK.0b013e3181f48987","volume":"35","author":"S Hagiwara","year":"2011","unstructured":"Hagiwara S et al (2011) Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 35(3):289\u2013292","journal-title":"Shock"},{"issue":"6","key":"123_CR77","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1538-7836.2009.03352.x","volume":"7","author":"M Seidel","year":"2009","unstructured":"Seidel M et al (2009) Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost 7(6):1030\u20131032","journal-title":"J Thromb Haemost"},{"issue":"4","key":"123_CR78","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1160\/TH14-12-1007","volume":"114","author":"SB Larsen","year":"2015","unstructured":"Larsen SB et al (2015) The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost 114(4):519\u2013529","journal-title":"Thromb Haemost"},{"issue":"5","key":"123_CR79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12185-012-1188-5","volume":"96","author":"F Moheimani","year":"2012","unstructured":"Moheimani F, Jackson DE (2012) P2Y12 receptor: platelet thrombus formation and medical interventions. Int J Hematol 96(5):572\u2013587","journal-title":"Int J Hematol"},{"issue":"8","key":"123_CR80","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana P et al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108(8):989\u2013995","journal-title":"Circulation"},{"issue":"24","key":"123_CR81","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana P et al (2003) P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 108(24):2971\u20132973","journal-title":"Circulation"},{"issue":"3","key":"123_CR82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijcard.2007.12.118","volume":"133","author":"P Staritz","year":"2009","unstructured":"Staritz P et al (2009) Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 133(3):341\u2013345","journal-title":"Int J Cardiol"},{"key":"123_CR83","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2350-8-59","volume":"8","author":"U Cavallari","year":"2007","unstructured":"Cavallari U et al (2007) Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet 8:59","journal-title":"BMC Med Genet"},{"issue":"4","key":"123_CR84","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.thromres.2009.10.014","volume":"125","author":"L Bonello","year":"2010","unstructured":"Bonello L et al (2010) Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 125(4):e167\u2013e170","journal-title":"Thromb Res"},{"issue":"3","key":"123_CR85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.mbc.0000164429.21040.0a","volume":"16","author":"N Beckerath von","year":"2005","unstructured":"von Beckerath N et al (2005) P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 16(3):199\u2013204","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"123_CR86","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","volume":"116","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ et al (2005) Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 116(6):491\u2013497","journal-title":"Thromb Res"},{"issue":"7","key":"123_CR87","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.STR.0000169922.79281.a5","volume":"36","author":"S Ziegler","year":"2005","unstructured":"Ziegler S et al (2005) Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 36(7):1394\u20131399","journal-title":"Stroke"},{"issue":"4","key":"123_CR88","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/09537100500475844","volume":"17","author":"SM Smith","year":"2006","unstructured":"Smith SM et al (2006) Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 17(4):250\u2013258","journal-title":"Platelets"},{"issue":"4","key":"123_CR89","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2125.2007.03044.x","volume":"65","author":"A Bierend","year":"2008","unstructured":"Bierend A et al (2008) P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. Br J Clin Pharmacol 65(4):540\u2013547","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"123_CR90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11302-011-9217-z","volume":"7","author":"M Cattaneo","year":"2011","unstructured":"Cattaneo M (2011) Molecular defects of the platelet P2 receptors. Purinergic Signal 7(3):333\u2013339","journal-title":"Purinergic Signal"},{"issue":"11","key":"123_CR91","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V80.11.2787.2787","volume":"80","author":"M Cattaneo","year":"1992","unstructured":"Cattaneo M et al (1992) Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 80(11):2787\u20132796","journal-title":"Blood"},{"issue":"11","key":"123_CR92","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1161\/01.ATV.20.11.e101","volume":"20","author":"M Cattaneo","year":"2000","unstructured":"Cattaneo M et al (2000) Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet \u2018primary secretion defect\u2019 are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 20(11):E101\u2013E106","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"123_CR93","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2141.1994.tb05123.x","volume":"88","author":"M Cattaneo","year":"1994","unstructured":"Cattaneo M et al (1994) Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP. Br J Haematol 88(4):826\u2013829","journal-title":"Br J Haematol"},{"issue":"1","key":"123_CR94","first-page":"87","volume":"97","author":"PV Halushka","year":"1981","unstructured":"Halushka PV et al (1981) Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97(1):87\u201396","journal-title":"J Lab Clin Med"},{"issue":"7","key":"123_CR95","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","volume":"26","author":"JA Colwell","year":"2003","unstructured":"Colwell JA, Nesto RW (2003) The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26(7):2181\u20132188","journal-title":"Diabetes Care"},{"issue":"8","key":"123_CR96","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","volume":"54","author":"DJ Angiolillo","year":"2005","unstructured":"Angiolillo DJ et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8):2430\u20132435","journal-title":"Diabetes"},{"issue":"2","key":"123_CR97","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","volume":"119","author":"R Marcucci","year":"2009","unstructured":"Marcucci R et al (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2):237\u2013242","journal-title":"Circulation"},{"issue":"2","key":"123_CR98","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2006.03.038","volume":"48","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48(2):298\u2013304","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"123_CR99","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11239-013-0966-0","volume":"37","author":"M Leoncini","year":"2014","unstructured":"Leoncini M et al (2014) Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. J Thromb Thrombolysis 37(4):427\u2013434","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"123_CR100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/01.ATV.0000199519.37089.a0","volume":"26","author":"IA Ferreira","year":"2006","unstructured":"Ferreira IA et al (2006) Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 26(2):417\u2013422","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"123_CR101","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/1076029614564208","volume":"21","author":"R Robledo-Nolasco","year":"2015","unstructured":"Robledo-Nolasco R et al (2015) Efficacy of change to new P2Y12 receptor antagonists in patients high on treatment platelet reactivity undergoing percutaneous coronary intervention. Clin Appl Thromb Hemost 21(7):619\u201325","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"123_CR102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ccd.24416","volume":"81","author":"P Capranzano","year":"2013","unstructured":"Capranzano P et al (2013) Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv 81(1):42\u201349","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"123_CR103","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1160\/TH13-01-0004","volume":"110","author":"U Baber","year":"2013","unstructured":"Baber U et al (2013) Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost 110(1):118\u2013123","journal-title":"Thromb Haemost"},{"issue":"8","key":"123_CR104","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/ndt\/gft027","volume":"28","author":"O Morel","year":"2013","unstructured":"Morel O et al (2013) Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 28(8):1994\u20132002","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"123_CR105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","volume":"113","author":"RT Dorsam","year":"2004","unstructured":"Dorsam RT, Kunapuli SP (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113(3):340\u2013345","journal-title":"J Clin Invest"},{"issue":"2","key":"123_CR106","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","volume":"50","author":"NA Farid","year":"2010","unstructured":"Farid NA, Kurihara A, Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50(2):126\u2013142","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"123_CR107","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1160\/TH11-06-0400","volume":"106","author":"L Hu","year":"2011","unstructured":"Hu L et al (2011) BF061, a novel antiplatelet and antithrombotic agent targeting P2Y(1)(2) receptor and phosphodiesterase. Thromb Haemost 106(6):1203\u20131214","journal-title":"Thromb Haemost"},{"key":"123_CR108","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(15)60213-6","volume":"386","author":"SD Wiviott","year":"2015","unstructured":"Wiviott SD, Steg PG (2015) Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 386:292\u2013302","journal-title":"Lancet"},{"issue":"1","key":"123_CR109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2044.2003.02960.x","volume":"58","author":"PC Kam","year":"2003","unstructured":"Kam PC, Nethery CM (2003) The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 58(1):28\u201335","journal-title":"Anaesthesia"},{"issue":"8","key":"123_CR110","first-page":"357","volume":"34","author":"J Kuzniar","year":"1996","unstructured":"Kuzniar J et al (1996) Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 34(8):357\u2013361","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"123_CR111","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"ME Bertrand","year":"2000","unstructured":"Bertrand ME et al (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102(6):624\u2013629","journal-title":"Circulation"},{"issue":"1","key":"123_CR112","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00005344-200401000-00019","volume":"43","author":"P Belanger","year":"2004","unstructured":"Belanger P et al (2004) Effects of high ticlopidine doses on platelet function in acute coronary syndrome patients. J Cardiovasc Pharmacol 43(1):128\u2013132","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"123_CR113","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2008.12.019","volume":"157","author":"RA Byrne","year":"2009","unstructured":"Byrne RA et al (2009) Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. Am Heart J 157(4):620\u20134.e2","journal-title":"Am Heart J"},{"issue":"24","key":"123_CR114","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA et al (2014) 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64(24):e139\u2013e228","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"123_CR115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.amjcard.2013.03.008","volume":"112","author":"G Patti","year":"2013","unstructured":"Patti G et al (2013) Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). Am J Cardiol 112(2):162\u2013168","journal-title":"Am J Cardiol"},{"issue":"1","key":"123_CR116","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ccd.24776","volume":"82","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT et al (2013) 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 82(1):E1\u2013E27","journal-title":"Catheter Cardiovasc Interv"},{"issue":"19","key":"123_CR117","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jacc.2011.02.011","volume":"57","author":"RS Wright","year":"2011","unstructured":"Wright RS et al (2011) 2011 ACCF\/AHA focused update incorporated into the ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57(19):e215\u2013e367","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"123_CR118","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1191\/135886398676216245","volume":"3","author":"K Schror","year":"1998","unstructured":"Schror K (1998) Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 3(3):247\u2013251","journal-title":"Vasc Med"},{"issue":"2","key":"123_CR119","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11606-012-2208-0","volume":"28","author":"EL Grove","year":"2013","unstructured":"Grove EL et al (2013) Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 28(2):216\u2013222","journal-title":"J Gen Intern Med"},{"key":"123_CR120","doi-asserted-by":"crossref","unstructured":"Agewall S et al (2013) Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34(23):1708\u20131713, 1713a\u20131713b","DOI":"10.1093\/eurheartj\/eht042"},{"issue":"11","key":"123_CR121","first-page":"961","volume":"52","author":"SN Li","year":"2013","unstructured":"Li SN et al (2013) The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome. Zhonghua Nei Ke Za Zhi 52(11):961\u2013965","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"123_CR122","first-page":"450814","volume":"2014","author":"J Su","year":"2014","unstructured":"Su J et al (2014) Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int 2014:450814","journal-title":"Biomed Res Int"},{"issue":"1","key":"123_CR123","first-page":"97","volume":"29","author":"I O","year":"2013","unstructured":"O I et al (2013) Evaluation of Aspirin and Clopidogrel resistance in patients with Acute Coronary Syndrome by using Adenosine Diphosphate Test and Aspirin Test. Pak J Med Sci 29(1):97\u2013102","journal-title":"Pak J Med Sci"},{"issue":"4","key":"123_CR124","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/09537104.2012.693992","volume":"24","author":"R Kar","year":"2013","unstructured":"Kar R et al (2013) Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets 24(4):297\u2013302","journal-title":"Platelets"},{"key":"123_CR125","unstructured":"Wang A, Lella LK, Brener SJ (2014) Efficacy and safety of prasugrel compared With clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Ther 2014 [Epub ahead of print]"},{"issue":"4","key":"123_CR126","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/17425255.2014.890589","volume":"10","author":"JC Coons","year":"2014","unstructured":"Coons JC et al (2014) Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. Expert Opin Drug Metab Toxicol 10(4):609\u2013620","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"20","key":"123_CR127","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"4","key":"123_CR128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11239-014-1139-5","volume":"39","author":"M Almendro-Delia","year":"2015","unstructured":"Almendro-Delia M et al (2015) Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the \u2018real world\u2019. J Thromb Thrombolysis 39(4):499\u2013507","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"123_CR129","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jcpt.12209","volume":"39","author":"WH Olson","year":"2014","unstructured":"Olson WH et al (2014) Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. J Clin Pharm Ther 39(6):663\u2013672","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"123_CR130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5603\/CJ.a2014.0026","volume":"21","author":"M Kozinski","year":"2014","unstructured":"Kozinski M et al (2014) Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J 21(5):547\u2013556","journal-title":"Cardiol J"},{"issue":"12","key":"123_CR131","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt JT et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5(12):2429\u20132436","journal-title":"J Thromb Haemost"},{"issue":"5","key":"123_CR132","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","volume":"66","author":"R Teng","year":"2010","unstructured":"Teng R, Butler K (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 66(5):487\u2013496","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"123_CR133","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Oestreich JH (2014) Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 34(10):1077\u20131090","journal-title":"Pharmacotherapy"},{"issue":"1","key":"123_CR134","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","volume":"70","author":"K Butler","year":"2010","unstructured":"Butler K, Teng R (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 70(1):65\u201377","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"123_CR135","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng R et al (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38(9):1514\u20131521","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"123_CR136","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","volume":"3","author":"US Tantry","year":"2010","unstructured":"Tantry US et al (2010) First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 3(6):556\u2013566","journal-title":"Circ Cardiovasc Genet"},{"issue":"11","key":"123_CR137","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057","journal-title":"N Engl J Med"},{"issue":"19","key":"123_CR138","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"RF Storey","year":"2007","unstructured":"Storey RF et al (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50(19):1852\u20131856","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"123_CR139","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/2047487314533215","volume":"22","author":"MR Patel","year":"2015","unstructured":"Patel MR et al (2015) Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol 22(6):734\u201342","journal-title":"Eur J Prev Cardiol"},{"key":"123_CR140","first-page":"1272","volume":"373","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 373:1272\u20131273","journal-title":"N Engl J Med"},{"issue":"1","key":"123_CR141","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/09537104.2013.867427","volume":"26","author":"R Shah","year":"2015","unstructured":"Shah R et al (2015) Ticagrelor as an alternative in clopidogrel-associated neutropenia. Platelets 26(1):80\u201382","journal-title":"Platelets"},{"issue":"6","key":"123_CR142","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH12-08-0547","volume":"108","author":"M Cattaneo","year":"2012","unstructured":"Cattaneo M, Faioni EM (2012) Why does ticagrelor induce dyspnea? Thromb Haemost 108(6):1031\u20131036","journal-title":"Thromb Haemost"},{"issue":"4","key":"123_CR143","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/17425255.2015.1021330","volume":"11","author":"E Tamborini Permunian","year":"2015","unstructured":"Tamborini Permunian E et al (2015) Cangrelor for the treatment of arterial thrombosis: pharmacokinetics\/pharmacodynamics and clinical data. Expert Opin Drug Metab Toxicol 11(4):625\u2013637","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"123_CR144","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","volume":"50","author":"WS Akers","year":"2010","unstructured":"Akers WS et al (2010) Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 50(1):27\u201335","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"123_CR145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","volume":"63","author":"P Genereux","year":"2014","unstructured":"Genereux P et al (2014) Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 63(7):619\u2013629","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"123_CR146","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fca.10.67","volume":"6","author":"M Ueno","year":"2010","unstructured":"Ueno M, Rao SV, Angiolillo DJ (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol 6(4):445\u2013453","journal-title":"Future Cardiol"},{"issue":"1","key":"123_CR147","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1574890109666140610153605","volume":"9","author":"I Bonadei","year":"2014","unstructured":"Bonadei I et al (2014) New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Recent Pat Cardiovasc Drug Discov 9(1):22\u201327","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"1","key":"123_CR148","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"S Leonardi","year":"2010","unstructured":"Leonardi S et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160(1):65\u201372","journal-title":"Am Heart J"},{"issue":"3","key":"123_CR149","first-page":"340","volume":"11","author":"JH Oestreich","year":"2010","unstructured":"Oestreich JH (2010) Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 11(3):340\u2013348","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"123_CR150","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"RC Welsh","year":"2012","unstructured":"Welsh RC et al (2012) A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 5(3):336\u2013346","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"123_CR151","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/mol.112.082198","volume":"83","author":"P Schmidt","year":"2013","unstructured":"Schmidt P et al (2013) Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12. Mol Pharmacol 83(1):256\u2013266","journal-title":"Mol Pharmacol"},{"issue":"5","key":"123_CR152","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCULATIONAHA.112.000799","volume":"128","author":"M Schaff","year":"2013","unstructured":"Schaff M et al (2013) Integrin alpha6beta1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis. Circulation 128(5):541\u2013552","journal-title":"Circulation"},{"issue":"10","key":"123_CR153","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/phar.1471","volume":"34","author":"LH Waite","year":"2014","unstructured":"Waite LH, Phan YL, Spinler SA (2014) Cangrelor: a novel intravenous antiplatelet agent with a questionable future. Pharmacotherapy 34(10):1061\u20131076","journal-title":"Pharmacotherapy"}],"container-title":["Advances in Experimental Medicine and Biology","Thrombosis and Embolism: from Research to Clinical Practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2016_123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:39:47Z","timestamp":1601059187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2016_123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319221076","9783319221083"],"references-count":153,"URL":"https:\/\/doi.org\/10.1007\/5584_2016_123","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}